Suspension of Products. BSM and/or its licensors may suspend Customer’s Subscription Plans or any User’s right to access or use any portion of Products, or to connect Products to Customer Third Party Applications, if BSM determines that Customer’s or Users’ use of Products, or Customer Third Party Applications, (i) pose a security risk to Products or any third party, (ii) may adversely impact Products, or the networks or data of any other BSM customer, business partner or service provider, (iii) do not comply with the Acceptable Use Policy or applicable law, or (iv) may subject BSM, or any third party, to liability. BSM will use commercially reasonable efforts under the circumstances to provide Customer with notice and an opportunity to remedy such violation or threat prior to any such suspension, and to reinstate such Products as soon as reasonably practicable following correction of the issue.
Suspension of Products. If Business Entity fails to maintain proper security, fails to properly maintain its accounts in good standing or is in violation of any provision of the CASH MANAGEMENT SYSTEM SERVICES AGREEMENT, The Bank may immediately suspend access and use of all Products. Reinstatement to use Products may require Business Entity to re-apply and obtain approval from The Bank’s Credit Committee or two executive officers.
Suspension of Products. No product of the Target Companies has been the subject of, or subject to (as applicable), any recall, suspension, market withdrawal or seizure, any warning letter or other written communication asserting lack of compliance with any applicable Law. No clinical trial of any product of the Target Companies has been suspended, put on hold or terminated prior to completion as a result of any action by any Governmental Authority or voluntarily. The studies, tests and preclinical and clinical trials conducted relating to the product of the Target Companies are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards at the time when conducted. The Target Companies have not received any notices or correspondence from any Governmental Authority requiring the termination, suspension, or material modification or clinical hold of any such studies, tests or preclinical or clinical trials conducted by or on behalf of the Target Companies. To the knowledge of the Representing Parties, there has been no indication that the FDA, EMEA or any other Governmental Authority currently has any material concerns with any product of the Target Companies, nor has any Target Company been advised of any material deficiencies or non-compliance which could reasonably be expected to lead to sanctions or materially adversely affect the certifications of the Target Companies’ facilities, nor has any product of the Target Companies, to the knowledge of each Representing Party, suffered any material adverse event in any clinical trial. To the knowledge of each Representing Party, no event has occurred or circumstance exists which could reasonably be expected to give rise to or serve as a basis for any of the foregoing events described in this Section 4.42. The Target Companies have previously made available to the Purchaser (i) all material correspondence with Governmental Authority and pending applications (including the EMEA and the FDA); and (ii) any and all adverse event reports with respect to the products of the Target Companies, in the case of each of clauses (i) and (ii), in the possession or control of the Target Companies. The descriptions of the results of such studies, tests and trials provided to the Purchaser are accurate in all material respects. ARTICLE V INTENTIONALLY OMITTED ARTICLE VI
Suspension of Products. BSM and/or its licensors may suspend Customer’s Flex Subscription Plans and access or use of any portion of Flex Products, if BSM determines that Customer’s use of Flex Products, (i) pose a security risk to Flex Products or any third party, (ii) may adversely impact Flex Products, or the networks or data of any other BSM customer, business partner or service provider, or (iii) may subject BSM, or any third party, to liability. BSM will use commercially reasonable efforts under the circumstances to provide Customer with notice and an opportunity to remedy such violation or threat prior to any such suspension, and to reinstate such Flex Products as soon as reasonably practicable following correction of the issue.
Suspension of Products. Unless specified otherwise, if Customer's account is seven (7) days or more overdue, in addition to any of its other rights or remedies (including but not limited to any termination rights set forth herein), Kyoo reserves the right to suspend Customer's access to the applicable Product (and any related products or/and services) without liability to Customer until such amounts are paid in full. Kyoo also reserves the right to suspend Customer's access to the Products without liability to Customer if Customer's use of the Products is in violation of the AUP.
Suspension of Products
